Can I Take Vitamin B6 with Farxiga (Dapagliflozin)?

What Is Farxiga and How Does It Work?

Dapagliflozin (Farxiga, AstraZeneca) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three distinct indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) with albuminuria. The drug blocks renal glucose reabsorption in the proximal tubule, causing roughly 70 grams of glucose to spill into the urine each day at the 10 mg dose.

Dapagliflozin Metabolic Pathway

The primary metabolic route for dapagliflozin is glucuronidation by UGT1A9 in the liver and kidneys, producing the inactive metabolite dapagliflozin-3-O-glucuronide. CYP450 enzymes play a minimal role. This matters for supplement interactions because most vitamin-drug interactions operate through CYP3A4, CYP2C9, or P-glycoprotein. Pyridoxine does not meaningfully inhibit UGT1A9 at any clinically plausible dietary dose, which is the mechanistic basis for the absence of a pharmacokinetic interaction. The FDA prescribing label confirms that dapagliflozin is not a CYP inhibitor or inducer. [1]

Clinical Trial Overview

Three major outcome trials established dapagliflozin's risk-benefit profile. DECLARE-TIMI 58 (N=17,160) demonstrated a significant reduction in hospitalizations for heart failure and renal composite endpoints in patients with type 2 diabetes. [2] DAPA-HF (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74; 95% CI 0.65-0.85; P<0.001). [3] DAPA-CKD (N=4,304) showed a 39% relative risk reduction in eGFR decline, end-stage kidney disease, or renal or cardiovascular death (HR 0.61; 95% CI 0.51-0.72; P<0.001). [4] None of these trials evaluated vitamin co-supplementation, but their adverse event profiles provide a baseline for monitoring.

What Is Vitamin B6 and Why Do People Take It?

Vitamin B6 refers to a family of six related compounds: pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms. Pyridoxal-5-phosphate (PLP) is the biologically active coenzyme form. Adults need 1.3-1.7 mg per day from food alone; the tolerable upper intake level (UL) set by the National Institutes of Health is 100 mg per day for adults. [5]

Common Reasons for B6 Supplementation in Diabetes Patients

People with type 2 diabetes take vitamin B6 for several reasons. Metformin use reduces B12 and, in some cohorts, B6 levels. Peripheral neuropathy is prevalent in long-standing diabetes, and some patients seek B vitamins believing they support nerve health. Premenstrual syndrome management and morning sickness protocols also drive B6 use. A 2018 NHANES analysis estimated that roughly 28% of U.S. Adults supplement with B vitamins, including a disproportionately high rate among adults managing chronic disease. [6]

B6 Deficiency and Diabetes

Chronic hyperglycemia may alter B6 metabolism. PLP acts as a cofactor in over 100 enzymatic reactions, including transamination and homocysteine remethylation. Low PLP status has been associated with elevated inflammatory markers in patients with type 2 diabetes in a cross-sectional analysis published in the American Journal of Clinical Nutrition. [7] Whether correcting modest B6 deficiency through supplementation improves glycemic or neuropathic outcomes remains a subject of ongoing study rather than established guideline-level guidance.

Is There a Direct Pharmacokinetic Interaction Between Dapagliflozin and Vitamin B6?

No pharmacokinetic interaction has been identified between dapagliflozin and vitamin B6 at any dose found in commercially available supplements. This section explains why.

Absorption

Dapagliflozin reaches maximum plasma concentration (Tmax) roughly 1-2 hours after oral ingestion. Its oral bioavailability is approximately 78% and is not meaningfully affected by food or co-ingested water-soluble vitamins. [1] Pyridoxine is absorbed in the jejunum via a saturable, concentration-dependent process; at doses above 200 mg the passive diffusion route supplements active transport, but neither mechanism competes with or influences SGLT2-inhibitor absorption. [8]

Protein Binding and Distribution

Dapagliflozin is approximately 91% bound to plasma proteins, primarily albumin. Pyridoxal-5-phosphate is also highly protein-bound (about 50-80%). There is a theoretical concern with two highly protein-bound compounds displacing each other, but this mechanism rarely produces clinically significant interactions unless the displaced drug has a narrow therapeutic index. Dapagliflozin's therapeutic index is wide. [1]

Elimination

Dapagliflozin's half-life is approximately 12.9 hours; it is predominantly renally excreted as glucuronide. Pyridoxine's half-life is 15-20 days for tissue stores; urinary pyridoxic acid accounts for most daily elimination. These pathways do not compete or overlap. [5]

Pharmacodynamic Considerations: Where to Watch Carefully

Even when two agents do not interfere at the pharmacokinetic level, they may affect the same organ system in ways that require monitoring. For dapagliflozin and vitamin B6, two pharmacodynamic areas deserve attention.

Peripheral Neuropathy: Opposing and Additive Risk

Diabetic peripheral neuropathy (DPN) affects an estimated 50% of patients with long-standing type 2 diabetes. [9] SGLT2 inhibitors, including dapagliflozin, have not been shown to worsen peripheral nerve function. Vitamin B6 at doses above 200 mg per day has independently caused sensory peripheral neuropathy in documented case series and controlled observations. The FDA strengthened the warning on high-dose B6 supplements in 2023, noting that doses as low as 150-200 mg per day taken chronically may produce tingling, numbness, and ataxia. [10] For a patient already at risk for DPN because of diabetes, adding unnecessary high-dose B6 supplements compounds the diagnostic challenge: if numbness worsens, determining whether the cause is glycemic injury, B6 toxicity, or another etiology becomes difficult without stopping the supplement.

The ADA Standards of Medical Care in Diabetes 2024 states: "Routine supplementation with antioxidants, such as vitamins E and C and carotene, is not advised because of lack of evidence of efficacy and concern related to long-term safety." [11] While this specific language targets antioxidants, the ADA's broader recommendation is to obtain micronutrients from food and to use supplements only when a documented deficiency exists. [11]

Urinary Tract Infections and Supplement Quality

Dapagliflozin increases urinary glucose concentration, which modestly elevates urinary tract infection (UTI) risk. In DECLARE-TIMI 58, genital mycotic infections occurred in 6.6% of women in the dapagliflozin group versus 1.3% with placebo. [2] Some high-dose B6 products contain inactive fillers, sugar alcohols, or herbal blends. Patients should choose third-party-tested products (NSF Certified, USP Verified, or Informed Sport) to avoid glucose-containing excipients that could theoretically influence urinary sugar load, though this remains a theoretical rather than documented concern.

Safe Dose Ranges and Practical Guidance

The following tiered framework summarizes clinical decision-making when a patient asks about combining vitamin B6 with dapagliflozin.

Tier 1: Dietary and Low-Dose Supplementation (up to 10 mg/day)

This range covers most multivitamins and B-complex products. No interaction risk. No dose separation required. Patients may take these with or without dapagliflozin at any time of day.

Tier 2: Moderate Supplementation (10-100 mg/day)

This range covers dedicated B6 supplements marketed for mood, PMS, or nerve support. Still within the NIH tolerable upper intake level of 100 mg/day. [5] No pharmacokinetic concern with dapagliflozin. Monitor for tingling or numbness at annual foot exams. Confirm no duplicate sources (some B-complex plus standalone B6 can push total daily dose above 100 mg without the patient realizing it).

Tier 3: High-Dose Supplementation (100-500 mg/day)

This range exceeds the NIH UL. High-dose B6 in this range has been used off-label for premenstrual dysphoric disorder and isoniazid-induced neuropathy prophylaxis, sometimes at 50-100 mg per day. Above 200 mg per day, sensory neuropathy risk rises. Patients on dapagliflozin for diabetes or CKD already carry elevated neuropathy risk. A prescriber should document a clear indication, establish a baseline neurological exam, and set a defined treatment duration before initiating this range. [10]

Tier 4: Very High Doses (above 500 mg/day)

No evidence supports this dose range for any condition in dapagliflozin-treated patients. Avoid entirely without direct specialist oversight.

What Do Interaction Databases Say?

The Natural Medicines Database (formerly Natural Standard) rates the dapagliflozin-vitamin B6 interaction as having no known interaction based on available clinical evidence, a finding consistent with the mechanistic analysis above. Drugs.com and Medscape drug interaction checkers similarly return no flagged interaction between pyridoxine and any SGLT2 inhibitor as of early 2025. [12]

Neither the European Medicines Agency SmPC for Farxiga nor the FDA prescribing information lists vitamin B6 as a substance requiring caution. [1] The absence of a labeled interaction, combined with the mechanistic rationale from UGT1A9 metabolism, provides reasonable confidence that the combination is safe at evidence-based doses.

Special Populations

CKD Patients on Dapagliflozin

DAPA-CKD enrolled patients with eGFR 25-75 mL/min/1.73m2. [4] Renal clearance of pyridoxine metabolites decreases as eGFR falls, which means B6 accumulation is possible in moderate-to-severe CKD even at doses that would be excreted safely by healthy kidneys. Patients with CKD stage 3b or lower (eGFR <45) should keep supplemental B6 at or below 25 mg per day and have PLP levels checked at routine labs. [13]

Heart Failure Patients

Volume management is a priority in HFrEF patients on dapagliflozin. No specific B6 concern applies here beyond the standard neuropathy caution. DAPA-HF excluded patients with eGFR <25, and the heart failure population generally skews older, meaning baseline peripheral neuropathy rates are higher. [3]

Patients Also on Metformin

Metformin depletes vitamin B12, not B6 directly, though a 2010 study in the Archives of Internal Medicine (N=155) found that long-term metformin use was associated with lower B6 as well as B12 levels in some subjects. [14] For patients on metformin plus dapagliflozin, annual testing of B12 and, if symptomatic, B6 (as serum PLP) is reasonable. Replacing documented deficiencies is appropriate; prophylactic megadosing is not.

Pregnancy

Dapagliflozin is contraindicated in the second and third trimesters of pregnancy (FDA Pregnancy Category warning). [1] Pyridoxine at 10-25 mg per day is a first-line antiemetic for nausea in early pregnancy per ACOG guidelines. [15] These two situations should not overlap clinically, but if a patient becomes pregnant while on Farxiga, dapagliflozin must be stopped and B6 dosing revised with an obstetrician.

Monitoring Checklist for Clinicians

A brief checklist for any clinician whose patient asks about this combination:

1. Confirm the total daily B6 dose across all sources (multivitamin plus standalone supplement).
2. Ask about symptoms: tingling, burning, or numbness in the feet or hands.
3. Document a baseline 10-g monofilament foot exam if not done in the past 12 months.
4. Check eGFR. For eGFR <45, cap supplemental B6 at 25 mg/day.
5. Review the full supplement list for duplicate B-vitamin sources.
6. Advise the patient to use third-party-tested products.
7. Schedule a follow-up neurological symptom review in 3-6 months if they are taking more than 50 mg/day of B6.

The ADA 2024 Standards advise: "Before recommending vitamin and mineral supplementation to people with diabetes, assess for underlying deficiencies." [11] A serum PLP level above 20 nmol/L is generally considered adequate; supplementation is most defensible when PLP falls below this threshold. [5]

What to Tell Your Prescriber

Patients should inform their prescriber or pharmacist about all supplements, including vitamins, at every visit. The specific combination of vitamin B6 and dapagliflozin does not require urgent contact, but a routine disclosure at the next appointment is appropriate. If a patient develops new numbness, tingling, burning in the extremities, or balance problems while taking both, the supplement should be paused and the prescriber contacted within 48 hours to allow evaluation of both glycemic neuropathy and B6 toxicity as possible causes.

A 2022 systematic review published in Nutrients (N=23 studies, 1,849 participants) found that high-dose pyridoxine above 500 mg per day was the most consistent dose associated with sensory neuropathy, but individual case reports have implicated doses as low as 150 mg per day in susceptible individuals. [16] The study authors recommended that clinicians query B6 supplement use specifically when evaluating peripheral neuropathy, since patients often do not volunteer vitamin use as part of their medication history.